RediCare Wins American Heart Association Award for its Work in Primary Care
Dallas, USA, Nov 2020 -- RediCare won a Paul Dudley International Scholar Award at the American Heart Association – Scientific Sessions 2020, recently held in Dallas, US for its work in deploying RediCare Control in primary care.
Commenting on the award, Dr. Niall Colwell consultant cardiologist commented;
'We are delighted to be awarded the Paul Dudley International Scholar Award from the American Heart Association. The work showed how a Digital Therapeutic such RediCare Control can be so effective treating chronic conditions with a validated lifestyle therapy.
The magnitude of HbA1c reduction in those with type 2 diabetes was comparable to those found with commonly prescribed medications. In addition, a meaningful percentage (71.43%, of participants achieved a HbA1c value below or equal to the diabetic range 48 mmol/mol. We were encouraged to see efficacy in patients with diabetes of more than 5 years duration. Blood pressure reduction in stage 1 and prehypertensive participants was also comparable with low-dose antihypertensive medications. Triglyceride reductions were significant showing a 50.6% and 33% reduction in participants with high and borderline high triglyceride levels respectively.’
Participants were reassured that the digital therapeutic was recommended by their G.P. and that their G.P. was available to support their treatment with medication adjustments, advice, and support as needed. The study showed that the therapeutic fitted smoothly within the GP workflow. This is now further enhanced as G.P's can now refer patients to the therapeutic electronically via 'Healthlink', the national e-referral system.
RediCare is a digital therapeutics firm. With our core product RediCare ControlDTx patients are transforming their health across the spectrum of metabolic health. They are experiencing clinically significant reductions in Weight, HbA1c, Blood Pressure and improved Lipid profiles and PCOS remission. Many Type 2 Diabetic patients have reduced and eliminated their diabetes medications.
RediCare ControlDTx is creating a new normal in prescription digital therapeutics for treating cardiometabolic diseases. We envision a new way to treat diseases like Type 2 diabetes and heart disease by targeting the root cause, not just the effects, using prescription digital therapeutics to deliver personalized clinically validated lifestyle therapy.
RediCare partners with primary care practices in the UK and Ireland and serves over 140 corporate clients with chronic disease screening and management services.